Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects
with solid tumors or lymphoma. Both a capsule and a tablet formulation will be evaluated.
XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown
to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.